Physician profile
James E Thomas
NPI 1174672356
$7,028.55
in general payments reported to CMS, 2019-2025
38 companies · $226 in 2025
The $226 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,629 · 2020: $974 · 2021: $245 · 2022: $1,119 · 2023: $1,072 · 2024: $1,764 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,040 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,040.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $942.62 | 2022-2025 | Gocovri, Apokyn, Myobloc |
| Emd Serono, INC. | $792.12 | 2019-2024 | Mavenclad |
| Biogen, INC. | $758.82 | 2019-2024 | Spinraza, Qalsody, Vumerity |
| Genzyme Corporation | $586.35 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $553.73 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $448.29 | 2019-2024 | Ultomiris |
| Sk Life Science, INC. | $376.95 | 2020-2024 | |
| Amneal Pharmaceuticals LLC | $354.70 | 2019-2024 | Rytary, Ongentys 50mg Capsules 30 |
| Amgen INC. | $211.18 | 2019-2022 | |
| Abbvie INC. | $190.76 | 2021-2024 | Botox, Ubrelvy, Qulipta |
| Supernus Pharmaceuticals, INC. | $183.00 | 2019-2020 | |
| Pfizer INC. | $156.61 | 2023-2024 | |
| Genentech USA, INC. | $142.72 | 2019-2024 | Ocrevus |
| Shockwave Medical, INC | $139.10 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $134.11 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $124.18 | 2019-2023 | Briviact |
| Lilly USA, LLC | $105.96 | 2020-2024 | Emgality, Amyvid, Reyvow |
| Nevro Corp. | $99.41 | 2022-2023 | Senza |
| Acorda Therapeutics, INC | $90.66 | 2019 | |
| Tanabe Pharma America, INC. | $78.01 | 2019-2024 | |
| Argenx US, INC. | $68.51 | 2022 | |
| Lundbeck LLC | $68.06 | 2023-2024 | Vyepti |
| Kyowa Kirin, INC. | $66.37 | 2020-2024 | Nourianz |
| Ge Healthcare | $60.24 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $37.47 | 2023 | Ingrezza, Ongentys |
| Alnylam Pharmaceuticals INC. | $31.28 | 2020 | |
| Allergan, INC. | $30.82 | 2020 | |
| Upsher-Smith Laboratories LLC | $29.84 | 2019 | |
| Avion Pharmaceuticals | $22.50 | 2022 | |
| Mallinckrodt Hospital Products INC. | $20.84 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.83 | 2022 | |
| Midsouth Orthopedics INC. | $19.71 | 2022 | |
| Kci USA, INC. | $19.49 | 2022 | |
| Innocoll Pharmaceuticals Limited | $14.88 | 2022 | |
| Cardiva Medical, INC. | $13.68 | 2020 | |
| Acadia Pharmaceuticals INC | $13.60 | 2019 | |
| Neurelis, INC. | $12.53 | 2022 | |
| Corium, LLC | $9.62 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.